雾化两性霉素B脱氧胆酸盐维持治疗慢性肺曲霉病的印度单中心经验
该回顾性研究纳入36例慢性肺曲霉病患者,比较雾化两性霉素B脱氧胆酸盐隔日给药与每周6天给药在维持缓解中的疗效与安全性。结果显示6/7天方案维持缓解率显著高于隔日方案(84.2% vs 46.7%,P=0.020),复发率更低,但需前瞻性随机对照试验验证。
要点
- 雾化两性霉素B脱氧胆酸盐可使约三分之二CPA患者维持缓解。
- 每周6天给药方案维持缓解率显著优于隔日方案。
- 常见不良事件为支气管痉挛,少数因不耐受停药。
核心结论
- 雾化两性霉素B脱氧胆酸盐在三分之二CPA患者中维持了缓解,6/7天给药方案结局显著优于隔日方案。
研究设计与样本
- 回顾性研究,纳入36例CPA患者,接受雾化两性霉素B脱氧胆酸盐10 mg每日两次、隔日或每周6天给药。
主要发现
- 34例可评估患者中位随访27个月,23例(67.6%)在NAB治疗期间维持缓解。
- 6/7天组维持缓解16/19(84.2%),隔日组7/15(46.7%),P=0.020。
- CPA复发11例(32.4%),隔日组8/15(53.3%),6/7天组3/19(15.8%),P=0.020。
- 不良事件8例(22.2%),包括支气管痉挛5例和咯血1例,2例因不耐受停药。
临床怎么用
- 对于需要维持治疗的CPA患者,雾化两性霉素B脱氧胆酸盐可考虑作为维持治疗选择。
- 每周6天给药方案可能优于隔日方案,但需个体化评估耐受性。
局限性
- 回顾性设计,样本量小(36例),需前瞻性随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic pulmonary aspergillosis (CPA) requires prolonged oral azole therapy, yet 30%-40% experience relapse after treatment discontinuation. The role of nebulized amphotericin B (NAB) in CPA as a maintenance therapy remains unexplored. METHODS: We retrospectively reviewed CPA patients treated with NAB deoxycholate (10 mg twice daily) preparation administered either on alternate days (three times weekly) or six times weekly (6/7-day). The primary objective was to compare the efficacy and safety of these two dosage schedules in maintaining CPA remission. RESULTS: We included 36 subjects (28 chronic cavitary pulmonary aspergillosis, 8 chronic fibrosing pulmonary aspergillosis ). Most received oral itraconazole (n = 34) for a median duration of 12 months before NAB initiation. Patients received NAB on alternate days (n = 16) or 6/7-day (n = 20) for a median duration of 11 months. Of 34 evaluable patients with a median follow-up of 27 months, remission was maintained in 23 (67.6%) during NAB therapy, with significantly higher rates with 6/7-day versus alternate-day therapy (16/19 [84.2%] versus 7/15 [46.7%]; P = 0.020). CPA relapse occurred in 11 patients (32.4%), more frequently with alternate-day treatment (8/15 [53.3%] versus 3/19 [15.8]; P = 0.020). Adverse events occurred in eight patients (22.2%), including bronchospasm (n = 5) and haemoptysis (n = 1); two discontinued NAB due to intolerance. CONCLUSION: Nebulized amphotericin B deoxycholate maintained CPA remission in two-thirds of patients, with 6/7-day administration achieving significantly better outcomes than alternate-day therapy. Prospective randomized controlled trials are needed to establish NAB as standard maintenance therapy in CPA.
引用
- Sehgal IS, Agarwal R, Muthu V, et al. Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India. J Antimicrob Chemother. 2026. PMID: 42253040. doi:10.1093/jac/dkag200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。